DDO-5936

未知

DDO-5936

D647795-5mg

5mg

≥95%

-20°C储存

超低温冰袋运输

DDO-5936 is a potent and specific Hsp90-Cdc37 PPI inhibitor. DDO-5936 can be used for the research of colorectal cancer In Vitro DDO-5936 is a Hsp90-Cdc37 PPI inhibitor with potency and specificity through binding to a critical site on Hsp90 involving Glu47. MCE has not independently confirmed the accuracy of these methods. They are for reference only. In Vivo DDO-5936 (0~80 mg/kg; p.o.) shows effect at the high dose group . DDO-5936 is well tolerated for the absence of serious weight loss. DDO-5936 high dose groups show that tumor cells in the xenografts decreased significantly. DDO-5936 shows limited oral efficiency . MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model: Mice Dosage: 0~80 mg/kg Administration: P.o. Result: Showed a moderate effect at the high dose group. Form:Solid IC50& Target:Hsp90-Cdc37 PPI

DDO-5936 是一种强效的特异性 Hsp90-Cdc37 PPI 抑制剂。DDO-5936 可用于结直肠癌的研究。

2355377-13-6

C25H29N5O4S

495.6 g/mol

141756475

CC1=CC(=C(C(=C1)C)S(=O)(=O)N(CC(=O)O)C2=CC=C(C=C2)NC3=NC(=NC=C3)N4CCCC4)C

2-[4-[(2-pyrrolidin-1-ylpyrimidin-4-yl)amino]-N-(2,4,6-trimethylphenyl)sulfonylanilino]acetic acid

1S/C25H29N5O4S/c1-17-14-18(2)24(19(3)15-17)35(33,34)30(16-23(31)32)21-8-6-20(7-9-21)27-22-10-11-26-25(28-22)29-12-4-5-13-29/h6-11,14-15H,4-5,12-13,16H2,1-3H3,(H,31,32)(H,26,27,28)

IIPYRKNROAWEPK-UHFFFAOYSA-N

CC1=CC(=C(C(=C1)C)S(=O)(=O)N(CC(=O)O)C2=CC=C(C=C2)NC3=NC(=NC=C3)N4CCCC4)C

141756475

DMSO : 12.5 mg/mL (25.22 mM; ultrasonic and warming and heat to 60°C)

2

9

8

495.194 Da

495.194 Da

124.000 Ų

35

0

795.000

0

1

4.400